Immuno-Oncology Resource Center
Immuno-Oncology Resource Center
April 23, 2018
1 min read

CAR T-cell therapy pioneer among Time magazine’s 100 most influential people

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Carl June
Carl H. June

Carl H. June, MD, has been named to Time magazine’s 100 most influential people in the world for 2018.

June is professor of immunotherapy in the department of pathology and laboratory medicine at University of Pennsylvania’s Perelman School of Medicine, director of Center for Cellular Immunotherapy at Abramson Cancer Center, and director of Parker Institute for Cancer Immunotherapy at Penn.

June’s inclusion in the Time 100 recognizes his pioneering work developing chimeric antigen receptor (CAR) T-cell therapy. Clinical trials of CAR T-cell therapy began at Penn in 2010, and two of the first three patients who received the therapy for chronic lymphocytic leukemia remain in remission nearly 8 years later.

The FDA has approved two CAR T-cell therapies. One is indicated for treatment of certain children and young adults with acute lymphoblastic leukemia, and the other is indicated for treatment of certain forms of non-Hodgkin lymphoma.

“I’ve been fortunate that my work has given me the opportunity to improve the lives of others,” June said in a press release. “It’s truly an honor for our team to be included among so many other tremendous honorees.”